Specialty Contract Research Organizations (CROs) Market, 2016 - 2025


Dublin, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/gjvskd/specialty_cros) has announced the addition of the "Specialty CROs Market, 2016 - 2025" report to their offering.

The Specialty CROs Market, 2016-2025 report delivers a comprehensive study on Contract Research Organizations (CROs) that provide a specialized set of research capabilities centred on a particular stage of clinical development or a range of services in a focused therapeutic area. The outsourcing model has proven to be extremely beneficial to drug developers catering to the unmet research, clinical development and even regulatory needs of both established players and start-ups in the market.

The concept of specialty CROs continues to evolve as these organizations adopt new strategies to provide their sponsors improved services in terms of both quality and efficiency. Novel business models and strategic partnerships among established and emerging players have opened new avenues to effectively tackle issues such as rising development costs, inefficient protocols and unorganized business processes.

The report assesses key drivers that have governed the evolution of specialty CROs over the past several years, along with an elaborate discussion on the upcoming trends that will likely shape the market in the coming years. In fact, one of the primary objectives of this study is to develop an understanding of the likely future evolution of the market for specialty CROs over the short-term and long-term.

The study presents an in-depth analysis of a diverse set of specialty CROs on some of the key parameters such as geographical location, types of services being offered and focused therapeutic areas. In addition, it captures the potential growth areas that will likely present opportunities for these companies and sustain the pace of growth. It is worth highlighting that despite the fact that established pharmaceutical companies have in-house R&D and clinical development capabilities, the opportunity for specialty CROs is growing.

The future evolution of this market will be primarily driven by the relatively fast paced growth of the overall pharma industry and the innovations / developments taking place in R&D. The report provides short-midterm and long-term market forecasts for the period 2016-2020 and 2020-2025, respectively. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution.

The research, analysis and insights presented in this report are backed by a comprehensive survey on capabilities of several specialty CROs. For the purpose of our analysis, we also interviewed important stakeholders in this market to solicit their opinions around the future opportunities and challenges that must be considered for a more inclusive growth.

Example Highlights

- Over the last few years, a structural transformation in the primary CRO business model to a more strategic approach has revolutionized R&D outsourcing. Newer players providing specific capabilities in the R&D value chain have witnessed a gradual acceptance.
- During our research, we have identified over 200 specialty CROs after detailed due diligence of more than 1,000 CROs based on their specific capabilities and the range of services they provide. These specialty CROs collectively cater to the multitude of research services required by drug developers.
- The US, with -115 speciality CROs, has emerged as the primary hub of specialty CROs; this is followed by Europe with -60 CROs. India and China, where CROs offer a relatively higher cost optimized service portfolio, are emerging as new destinations; the level of activity, however, has been fairly limited so far.
- Though the broader contract research market is highly consolidated and dominated by a handful of bigger CROs, the market within the specialty CRO segment is highly fragmented. This is unlikely to change as biotech companies will continue to prefer outsourcing specific requirements of the clinical trials instead of outsourcing the entire clinical trial programme to an individual CRO.
- We expect the overall market of specialty CROs to more than double in the coming decade, growing at a CAGR of 8.6%. Specific areas of growth are likely to be driven by novel services and upcoming technologies resulting in cost optimization and improved outputs.
- Some of the niche opportunity areas / approaches include Health Economics and Outcomes Research (HEOR), adaptive trial designs, and eClinical solutions. Specifically, these areas typify a growing unmet need and represent untapped areas making outsourcing an attractive option.


Key Topics Covered:

1. Preface
1.1. Scope Of The Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. History
3.2. Traditional Contract Research Organisations
3.3. Specialty Contract Research Organisations

4. Specialty CROs: An Introduction
4.1. Chapter Overview
4.2. Importance Of Specialty CROs

5. Market Overview
5.1. Chapter Overview
5.2. Methodology
5.3. Specialty CROs: Global Landscape
5.4. Specialty CROs Focused On A Specific Service Capability
5.5. Specialty CROs Focused On Specific Therapeutic Area(S)

6. Specialty CROs: Focused On Services
6.1. Chapter Overview
6.2. CROs Focused On Preclinical Service Capabilities
6.3. CROs Focused On Clinical Service Capabilities

7. Specialty CROs: Focused On Therapeutic Areas
7.1. Chapter Overview
7.2. Specialty CROs Focused On Oncology
7.3. Specialty CROs Focused On Cardiovascular / Cardiology
7.4. Specialty CROs Focused On Metabolic Disorders
7.5. Specialty CROs Focused On Cns

8. Case Study I: Virtual CROs
8.1. Introduction To Virtual CROs
8.2. Frestedt
8.3. Insymbiosis
8.4. Osiris Pharma
8.5. Projectpharm
8.6. The Harte Group
8.7. Vxp Pharma

9. Case Study Ii: Full Service CROs
9.1. Introduction To Traditional CROs
9.2. Covance
9.3. Medis Research Group
9.4. Quintiles
9.5. Triclinium Clinical Trial Project Management

10. Market Forecast
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Global Specialty CROs Market, 2015-2025
10.4. Regional Specialty CROs Market, 2015 - 2025

11. Future Opportunities
11.1. Chapter Overview
11.2 The Changing Scenario Of Outsourcing
11.3. Health Economics And Outcomes Research (Heor) Studies
11.4. Adaptive Trial Design
11.5. Eclinical Solutions
11.6. Risk Based Monitoring (Rbm)
11.7. Digital CRO (DCRO)

12. Conclusion
12.1. A Widening Portfolio Of Services Governed By Industry Constraints
12.2. Closer Working Collaboration Is The Key To Success
12.3. Within Therapeutic Areas, Oncology Is The Flagbearer
12.4. Due To Several Niche Offerings, Specialty CRO Market Remains Fragmented
12.5. The Market Of Specialty CROs Is Likely To Sustain The Growth Momentum
12.6. Untapped Opportunity Areas Will Emerge As Key Growth Drivers In The Long-Term
12.7. Concluding Remarks

13. Interview Transcripts
13.1. Chapter Overview
13.2. Raf Magar, President, CRO And Outcomes Research, Ahrm
13.3. Jeffrey P. Kiplinger, President, Averica Discovery Services

14. Appendix 1: Tabulated Data

15. Appendix 2: List Of Companies And Organisations

16. Appendix 3: Service Map Glossary

Companies Mentioned

- Abiogenesis Clinpharm
- Accell Clinical Research
- Accelovance
- Aclires
- Acquipharma
- Afraxis
- Agence Africaine de Recherche en Santé Humaine
- Agility Clinical
- Agilux Laboratories
- AHRM
- AIT Bioscience
- Aklima Clinical Research
- Alera Labs
- Alimentix
- Alliance Pharma
- Allied Clinical Management
- Allostem Therapeutics
- Almedis
- Alpha CRO
- Alpha Stats
- Altair Clinical
- Altiora CRO
- Altree Healthcare
- Alturas Analytics
- Amarex Clinical Research
- Amclin Life Sciences
- American Physical Therapy Association
- AMSlab
- Anolinx
- APEX Research
- Appletree CI Group
- Applied Clinical Research & Consulting Group
- Applied Healthcare Resource Management
- Apricus Biosciences
- ARAC
- Arete Clinical Research
- Argonaut Private Equity
- Aris Global
- Arkios BioDevelopment International
- Association for Assessment and Accreditation of Laboratory Animal Care International
- Association of Clinical Research Organizations
- Association of Clinical Research Professionals
- Aston University
- Athena Discovery
- Atlantic Bone Screen
- Atuka
- Audubon PM Associates
- Auxilis Pharma
- Averica Discovery Services
- Avitacor
- Axonal
- B. McLaughlin Associates
- Banook Group
- Betagenex
- Biaffin GmbH & Co
- Biogen
- BioLink Life Sciences
- BioPharma Services
- Bio-Quant
- BioSkin CRO
- Biospective
- Biotrofix Preclinical CRO
- Bordeaux University
- Boston Biomedical Associates
- Boston Regulatory Consulting
- BRI Biopharmaceutical Research
- BTS Research
- Burrill & Company
- Cambridge Biomedical
- Canadian Council of Animal Care
- CAP Trials
- Cardialysis
- Cardiomedex
- CDIB Capital Investment
- Center Point Clinical Services
- Cerafor
- Charles River Laboratories
- Chimera Biotec
- Cica Biomedical
- CIDP Biotech India
- Cirion Clinical Trial Services
- CirQuest Labs
- ClinAudits
- ClinBAY
- ClinDatrix
- Clinical Research Consulting
- Clinilabs
- CliniRx Tangent Research
- ClinIST Research Education and Consulting
- Clinitrial CRO
- ClinROC
- Clinvest
- CMX Research
- CNBE
- Concentrics Research
- Courante Oncology
- Covance
- CPR Pharma Services
- CRC Pharma
- CRDE
- Creagen Biosciences
- CRO Solutions
- Cros NT
- Crown Bioscience
- Crownbio Taicang Biologics Division
- Crystal Pharmatech
- Cu Tech
- CuriRX
- Cyprotex
- Cytespace Africa
- DATATRAK International
- David H Murdock Research Institute
- DaVita Clinical Research
- DiaVacs
- Dinox
- Diverse Lynx
- DOCRO
- Dorizoe Lifesciences
- DSP Clinical Research
- DZS Clinical Services
- EarlyPhase Sciences
- Eastern Clinical Trials
- Eckert & Ziegler Vitalea Science
- Ecron Acunova
- Elucid Bioimaging
- EmpiriStat
- EMRI CRO Greece
- Encore Health Services
- Ephoran
- ERA Clinical
- Erudita Biotechnical
- EthosExcel
- Euprotec
- European Cardiovascular Research Institute
- European Food Safety Authority
- European Medical Writers Association
- Federation of European Laboratory Animal Science Association
- Fermish
- First Clinical Network
- Flow Contract Site Laboratory
- FlowMetric
- FluoFarma
- Foster Delivery Services
- Frenova Renal Research
- Frestedt
- Frontline Monitors
- Gadea Grupo Farmacéutico
- Gateway Pharmacology Laboratories
- Getz Pharma Research
- Global Specimen Solutions
- Greenville Health System
- Gubra
- Harlan Laboratories
- Health Canada
- Health Sciences Authority
- HealthLinx
- Hengrui Medicine
- HJ-Clinical Trial Consultancy
- Horizon Discovery
- Hospital Italiano of Buenos Aires
- Huntingdon Life Sciences
- IBT Management Corporation
- ICE Bioscience
- ICRC-Weyer
- IMMR
- Impact Pharmaceutical Services
- Inamed
- Inclinix
- Innova CRO
- Innovaderm Research
- InrexTest
- Institute for Translational Oncology Research
- InSymbiosis
- Integral Biosystems
- International Drug Development Institute
- Ionic Transport Assays
- IonsGate Preclinical Services
- IPSEN
- Iris Pharma
- Jasco Pharmaceuticals
- JV AgroBiotech
- KalVista Pharmaceuticals
- Karolinska Development
- KCAS
- KCRI
- Kiyatec
- Klinikos Consulting
- KPS
- LabCorp Clinical Trials
- Lekoko PMC
- LEMI
- Life Science Alley
- Lilly Asia Ventures
- Lotus Clinical Research
- LU Bioscience
- Marsico Lung Institute
- MCT
- Medelis
- Medepha
- Medicines and Healthcare Products Regulatory Agency
- Medicon Valley Inhalation Consortium
- Medis Research Group
- MedSource
- Merck Serono
- Mercodia
- Michigan Life Science and Innovation Center
- MicroConstants
- Midwest Melanoma Partnership
- miRagen Therapeutics
- MMS Holdings
- Modoc Research Services
- Molecular Imaging
- Molecular Response
- Montrium
- NAMSA Medvance
- Nanjing Biotech Innovation Corporation
- National Cancer Institute
- National Institutes of Health
- National Resource Center for Mutant Mice
- Neuregenix
- NeuroDiscovery
- Neuron Experts
- NeuroSciences
- New England Research Institute
- New York State Center of Excellence in Bioinformatics and Life Sciences
- NexMed
- Next Generation Clinical Research
- Novella Clinical
- NSF International
- Numira
- Nutrition Coordinating Center
- Octagon Research Solutions
- Oncotherapeutics
- Oneiric International
- OnkoDataMed
- OnPoint CRO
- OrbiMed Advisors
- Orbis Data Solutions
- Organon
- Osiris Pharma
- Oss lab
- P3 Research
- Pacific Nutritional Research
- PAIRimmune
- Panacea Pharmaceuticals
- Pfizer
- PharmaLegacy
- PharmaPhase Management
- PharSafer Associates
- Phenotype Expertise
- PhylogenX
- Physiogenex
- PhysioStim
- Pioneer Clinical Data
- Pneumolabs
- Preclinical Oncology Services
- Profil Institut für Stoffwechselforschungh
- ProjectPharm
- Prologue Research
- Prometrika
- ProNoxis
- ProQinase
- ProTrials
- Provonix
- QED Clinical Services
- QuailCRO
- Quanticate
- Quest Diagnostics
- Quintiles
- Redoxis
- Renaissance Associates
- RenaSci
- Research Dynamics Consulting Group
- Research Point Clinical
- Roche
- RxGen
- SAGE Labs
- Sahana Clinical Research
- SBH Sciences
- SCIderm
- Scimega
- SDS Clinical
- Servier
- Shanghai Institute of Materia Medica
- Shin Nippon Biomedical Laboratories
- Simbec Research
- Skills Alliance
- SMS-oncology
- Spirovation
- Sristek
- Stat Pro
- Surpass
- SwedenBIO
- Symbiance
- Symmetry Biosciences
- Synchrogenix
- SynCon International
- Synergo BioPharma
- Synergy
- Synsight
- Sysmex Corporation
- TAB Clinical Trials
- Tandem Labs
- TCNSC
- Team WomenMN
- Techtrials International
- TFS Trial Form Support
- The CID Group
- The Harte Group
- The Medical Affairs Company
- The Total Approach
- Therapeutic Goods Administration
- Therinova
- Tillväxtverket
- Topstone Research
- Toxikon Corporation
- Translational Research Institute
- Trial-IN
- Triclinium Clinical Research
- Tufts University
- Universidad de Valladolid
- University College Dublin
- University of Erlangen
- Vanton Research Laboratory
- Velesco Pharmaceutical Services
- Vinnova
- VirtualScopics
- Visionar Preclinical
- Voxcan
- VR Analytical
- VxP Pharma
- Wildcat Pharmaceutical Development Center
- William Harvey Research
- World Health Organization
- Xenometrics
- Xerox Corp
- Xstrahl
- YAKUMED
- 2KMM

For more information visit http://www.researchandmarkets.com/research/gjvskd/specialty_cros




            

Contact Data